Established in 1992, the 340B Drug Pricing Program has many nuances and applications to different situations. Fundamentally, it requires pharmaceutical manufacturers to sell outpatient drugs at significantly reduced prices to eligible safety-net hospitals and clinics, requires pharmaceutical manufacturers to provide up-front discounts and pharmaceutical manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices. The conditions of participation and compliance are not simple.
The goal of this webinar is to explain key facets of the 340B Program and delve into recent opinions from the U.S. Courts of Appeals for the Ninth Circuit and the Fourth Circuit.